Please assess the completion status of the following clinical trial:

Trial Title: A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must give their signed and dated written informed consent to participate.~* Subjects 40 years of age or older at Visit 1.~* Male or female subjects .~* An established clinical history of COPD.~* Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Visit 1.~* A post-albuterol/salbutamol FEV1/FVC ratio of \<0.70 and a post-albuterol/salbutamol FEV1 of \>=30 and \<= 70% of predicted normal values at Visit 1 calculated using NHANES III reference equations .~Exclusion Criteria:~* A current diagnosis of asthma~* Women who are pregnant of lactating or are planning on becoming pregnant during the study.~* Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.~* Participation in pulmonary rehabilitation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albuterol/salbutamol followed by ipratropium (Type: ACTIVE_COMPARATOR): Subjects will recieve daily albuterol/salbutamol followed by ipratropium which will be adminstered one hour after adminstration of albuterol/salbutamol
- Ipratropium followed by albuterol/salbutamol (Type: ACTIVE_COMPARATOR): Subjects will recieve daily ipratropium followed by albuterol/salbutamol which will be adminstered one hour after adminstration of ipratropium

Based on this trial design, predict the completion outcome and termination type (if applicable).